ArticleFrontiers in public health2025
Spatial and temporal analysis of viral hepatitis in mainland China from 2007 to 2023: implications for targeted public health interventions.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Viral hepatitis remains a major public health challenge in China, contributing significantly to global disease burden. Understanding spatiotemporal patterns is crucial for developing effective control strategies. Methods: We conducted spatiotemporal analysis of viral hepatitis surveillance data from 31 provinces in mainland China spanning 2007-2023, encompassing 21,346,298 reported cases of hepatitis A, B, C, and E. Methods included descriptive epidemiological analysis, spatial autocorrelation using Moran's Results: Hepatitis B dominated with 78.63% of cases, followed by hepatitis C at 12.51%. The annual incidence of hepatitis A decreased from 7.20 to 1.06 (85.3% reduction, APC = -15.2%); hepatitis C increased from 3.03 to 13.82 (356% growth, APC = +11.8%); hepatitis B showed slight decline (APC = -0.6%); and hepatitis E remained relatively stable (APC = +1.4%). Spatial autocorrelation analysis revealed significant clustering patterns (Global Moran's Conclusion: Our findings validate hepatitis A vaccination as a cost-effective elimination strategy that can be replicated in resource-limited settings; identify the need for immediate policy action on hepatitis C; and demonstrate that investment in transportation infrastructure can reduce hepatitis burden by improving healthcare access in remote areas. These studies provide theoretical references for China to achieve the 2030 elimination target and offer transferable strategies for countries facing similar geographical and socio-economic challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.